<DOC>
	<DOCNO>NCT02470585</DOCNO>
	<brief_summary>The focus study evaluate efficacy , safety , tolerability veliparib woman previously untreated , Stage III IV , high-grade serous , epithelial ovarian , fallopian tube , primary peritoneal cancer .</brief_summary>
	<brief_title>Veliparib With Carboplatin Paclitaxel Continuation Maintenance Therapy Subjects With Newly Diagnosed Stage III IV , High-grade Serous , Epithelial Ovarian , Fallopian Tube , Primary Peritoneal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Veliparib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>1 . Histologic diagnosis International Federation Gynecology Obstetrics ( FIGO ) Stage III IV epithelial ovarian , fallopian tube , primary peritoneal carcinoma , appropriate tissue available histologic evaluation . 2 . Highgrade serous adenocarcinoma 3 . Willing undergo test gBRCA . 4 . Adequate hematologic , renal , hepatic function . 5 . Neuropathy ( sensory motor ) less equal Grade 1 . 6 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 , 2 . 7 . Participants undergo primary cytoreductive surgery must enter 1 12 week surgery . Participants undergo interval surgery must tumor sample confirm histological diagnosis prior enrollment . 8 . Participants measurable disease nonmeasurable disease eligible . Participants may may cancerrelated symptom . 9 . Participant one follow available PD analyse include somatic BRCA testing : Archived diagnostic formalinfixed paraffin embed ( FFPE ) tumor tissue ; tumor tissue biopsy collect prior Cycle 1 Day 1 . 1 . Endometrioid adenocarcinoma , carcinosarcoma , undifferentiated carcinoma , mixed epithelial adenocarcinoma , adenocarcinoma otherwise specify , mucinous adenocarcinoma , clear cell adenocarcinoma , lowgrade serous adenocarcinoma , malignant Brenner 's tumor . 2 . Participants synchronous primary endometrial cancer , past history endometrial cancer unless follow condition meet : endometrial cancer stage great IA , vascular lymphatic invasion , poorly differentiate subtypes include serous , clear cell , FIGO grade 3 lesion . 3 . Participants evidence invasive malignancy present within last 3 year ( exception nonmelanoma skin cancer ) . Participants also exclude previous cancer treatment contraindicate protocol 's therapy . 4 . Received prior radiotherapy portion abdominal cavity pelvis . 5 . Received prior chemotherapy abdominal pelvic tumor . 6 . Clinically significant uncontrolled condition ( ) . 7 . Known history allergic reaction Cremophorpaclitaxel , carboplatin , AzoColourant Tartrazine ( also know FD &amp; C Yellow 5 E102 ) , AzoColourant Orange YellowS ( also know FD &amp; C Yellow 6 E110 ) know contraindication study supply drug . 8 . History evidence upon physical examination central nervous system ( CNS ) disease , include primary brain tumor , brain metastasis , history cerebrovascular accident ( CVA , stroke ) , transient ischemic attack ( TIA ) within 6 month Cycle 1 Day 1 .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Overall Survival</keyword>
	<keyword>BRCA</keyword>
	<keyword>Veliparib</keyword>
	<keyword>Ovarian</keyword>
	<keyword>Poly Adenosine Diphosphate ( ADP ) - Ribose Polymerase ( PARP )</keyword>
	<keyword>ABT-888</keyword>
	<keyword>Paclitaxel</keyword>
	<keyword>Carboplatin</keyword>
	<keyword>Randomized</keyword>
</DOC>